ObesityWeek

Ascletis reports preclinical results for oral and long-acting obesity drugs
Ascletis Pharma has presented preclinical results for an oral GLP-1R and GIPR combination and a long-acting triple agonist aimed at obesity treatment. The company said…
ResearchNovo reports about 21% weight loss for lower-dose CagriSema
Novo Nordisk says its investigational CagriSema combination produced estimated average weight loss of 20.7% and 21.0% after 68 weeks at two lower doses in the REDEFINE 9…